Latest News

Latest News

Weekly News Roundup | 2 November 2026

Weekly News Roundup | 2 November 2026

Life science news 2 November 2026: four approvals, three deals and a UK Budget investment package. Ferring has agreed to acquire Gameto in a deal worth up to $1.3825bn. The FDA granted accelerated approval to Voceryq for recurrent respiratory papillomatosis. The MHRA...

read more
What Are You Signing When the AI Wrote the Note?

What Are You Signing When the AI Wrote the Note?

Anyone who has finished an emergency shift knows the chart stack. The department is still loud, the next team has the board, and a column of unsigned notes waits on the workstation. You read each one, fix what's wrong, and sign. That signature has always meant...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Why Pharmaceutical Quality Cannot Be Tested Into a Product

Why Pharmaceutical Quality Cannot Be Tested Into a Product

In pharmaceutical manufacturing, quality control testing is often the point at which a product gets its final analytical assessment. But from my experience in pharmaceutical quality control, one principle is worth emphasizing: QC testing is essential, but QC testing...

read more
Fifty Patients, No Registry: MVA Research Meets in London

Fifty Patients, No Registry: MVA Research Meets in London

Mosaic variegated aneuploidy (MVA) is thought to affect fewer than 50 people worldwide. At that scale, ultra-rare disease research runs into a problem that funding alone does not solve. There is no cohort large enough to randomise. There is often no natural history...

read more
Semaglutide Patent Expiry: What Generics Did to Prices

Semaglutide Patent Expiry: What Generics Did to Prices

The semaglutide patent expiry of March 2026 has now had six months to work. The evidence is uneven. In India, prices fell by up to 70% within weeks. In Canada, generic pens reached pharmacies in May. In China, not one generic has been approved. Readers in the United...

read more
Freeze-Dried Does Not Mean Pathogen-Free

Freeze-Dried Does Not Mean Pathogen-Free

Once concentrated in commercial manufacturing, freeze-drying has entered home kitchens and small food businesses through countertop equipment. That shift has made freeze-dried food safety a live question for small operators. University of Minnesota Extension describes...

read more
Why Pharmaceutical Quality Cannot Be Tested Into a Product

Why Pharmaceutical Quality Cannot Be Tested Into a Product

In pharmaceutical manufacturing, quality control testing is often the point at which a product gets its final analytical assessment. But from my experience in pharmaceutical quality control, one principle is worth emphasizing: QC testing is essential, but QC testing...

read more
Fifty Patients, No Registry: MVA Research Meets in London

Fifty Patients, No Registry: MVA Research Meets in London

Mosaic variegated aneuploidy (MVA) is thought to affect fewer than 50 people worldwide. At that scale, ultra-rare disease research runs into a problem that funding alone does not solve. There is no cohort large enough to randomise. There is often no natural history...

read more
Semaglutide Patent Expiry: What Generics Did to Prices

Semaglutide Patent Expiry: What Generics Did to Prices

The semaglutide patent expiry of March 2026 has now had six months to work. The evidence is uneven. In India, prices fell by up to 70% within weeks. In Canada, generic pens reached pharmacies in May. In China, not one generic has been approved. Readers in the United...

read more
Freeze-Dried Does Not Mean Pathogen-Free

Freeze-Dried Does Not Mean Pathogen-Free

Once concentrated in commercial manufacturing, freeze-drying has entered home kitchens and small food businesses through countertop equipment. That shift has made freeze-dried food safety a live question for small operators. University of Minnesota Extension describes...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Twin B7-H3 ADC Wins in Seoul Leave the UK Route Unresolved

Twin B7-H3 ADC Wins in Seoul Leave the UK Route Unresolved

Two B7-H3 ADC readouts landed in the same Seoul session on 13 September 2026. Both reported a survival win in relapsed small cell lung cancer. Both trials ran entirely in China. Neither dataset, on its own, is a filing package for the FDA, the EMA or the MHRA. Two...

read more
Weekly News Roundup | 14 September 2026

Weekly News Roundup | 14 September 2026

Life science news 14 September 2026: two US approvals for rare diseases, a landmark antibody-drug conjugate readout, and two UK moves on pharmacy access and AI oversight. Scholar Rock’s Isembyld won FDA approval, described by the agency as the first SMA therapy to...

read more
Clinical Trials Roundup | 11 Sept 2026

Clinical Trials Roundup | 11 Sept 2026

Novo Nordisk’s semaglutide meets its primary endpoint in children aged six to under 12 in the Phase 3 STEP Young obesity trial, Novartis’s del-desiran misses its primary endpoint in the Phase 3 HARBOR study in myotonic dystrophy type 1, Pharvaris’s deucrictibant XR...

read more
The Other Half of Innovation

The Other Half of Innovation

What does the word "innovation" typically evoke in wound care? For many, it brings to mind a new biomaterial, a novel mechanism, or a breakthrough product supported by promising data and clinical validation. These advancements matter. But they raise a more fundamental...

read more

Further News

In Vivo Gene Editing Nears Its First FDA Decision: What the Data Shows

In vivo gene editing now has a fixed regulatory date. In April 2026, Intellia Therapeutics reported Phase 3 results for lonvo-z, a therapy that edits DNA inside the body. The company described the result as a global first for in vivo gene editing. In September, the US...

Anktiva NHS Access: Can UK Patients Get It for Bladder Cancer?

Anktiva NHS access has no NICE recommendation behind it. The medicine holds a UK licence for BCG-unresponsive bladder cancer. However, NICE ended its appraisal in June 2026 because ImmunityBio did not submit evidence. The question matters again because of a US...

Cresset’s Flare AI Client Turns Hours of Work into Minutes

Scientists can now connect company-approved AI providers such as Claude Code and GitHub Copilot directly to Flare, helping teams set up, execute, and analyze complex computational chemistry workflows in minutes not hours. CAMBRIDGE, UK, 6 October 2026 Drug discovery...

The National Priority Voucher: Inside the FDA’s Shortest Review Pathway

Last updated: 15 October 2026. Programme facts checked against FDA sources on that date. A national priority voucher can cut an FDA drug review from around ten months to one or two. The Commissioner’s National Priority Voucher (CNPV) is an FDA pilot programme rather...

Bispecific T-Cell Engagers in Refractory Autoimmune Disease

Bispecific T-cell engagers, originally developed to redirect immune responses against cancer, are being investigated as potential therapeutic candidates for treatment-refractory autoimmune connective tissue diseases. A 2026 study published in Nature Medicine reported...

Icotrokinra NHS Access: Will the Oral Psoriasis Pill Reach Patients?

Icotrokinra NHS access has no published timetable. As of 14 October 2026, LSDN searches found no UK marketing authorisation for icotrokinra. The drug is approved as Icotyde in the US and EU. The European Commission authorisation was announced on 21 September 2026....

When Familiar Is Not Documented: Mandatory GRAS and Traditional Botanicals

Longan was a familiar food in the home I grew up in. It was a tasty summer fruit we ate in southern China, much like an American family might think of mango. Years later, when I started making beverages in St. Louis, I used longan in a hydration drink, well before FDA...

Medicine Does Not Run on Blood Alone

Prevention-first urine diagnostics will depend not only on how accurately we can measure disease, but on how often and how easily people can be tested. Blood is medicine's default diagnostic medium for good reasons. It circulates through the whole body, carries a...

ALK7 Obesity Drugs: Who Is Developing Them After Roche’s Rona Deal?

Which companies are developing ALK7 obesity drugs? Roche’s Rona deal joins Arrowhead and GSK programmes, but human data remain early.

    What Pharma Can Learn From Retail as GLP-1 Demand Reshapes Healthcare

    Demand for weight-loss medicines in the UK has run well ahead of what the NHS can provide. Researchers at UCL estimate that 1.6 million adults in Great Britain used a medicine to lose weight between early 2024 and early 2025, and that a further 3.3 million were...

    Admilparant Approval: What the ALOFT-IPF Result Shows So Far

    Admilparant approval for idiopathic pulmonary fibrosis (IPF) is not yet decided, and LSDN found no announced regulatory filing. On 12 October 2026, Bristol Myers Squibb (BMS) reported that its phase 3 ALOFT-IPF trial met its primary endpoint. That was at the 60 mg...

    AI Can Accelerate Optimisation, But It Cannot Replace Biological Discovery

    Artificial intelligence is increasingly being integrated into the drug discovery process. From the identification of therapeutic targets to the prediction of molecular interactions and ranking of compounds to be developed further, the power of computational tools...

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.

    See More Articles

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.